Equities analysts expect Danaher Corporation (NYSE:DHR) to announce earnings of $0.95 per share for the current quarter, Zacks reports. Eight analysts have provided estimates for Danaher Corporation’s earnings. The highest EPS estimate is $0.96 and the lowest is $0.94. Danaher Corporation posted earnings per share of $0.87 during the same quarter last year, which suggests a positive year over year growth rate of 9.2%. The company is expected to issue its next quarterly earnings report on Thursday, October 19th.

On average, analysts expect that Danaher Corporation will report full-year earnings of $3.94 per share for the current financial year, with EPS estimates ranging from $3.91 to $3.96. For the next year, analysts forecast that the business will report earnings of $4.27 per share, with EPS estimates ranging from $4.20 to $4.35. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Danaher Corporation.

Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The firm had revenue of $4.51 billion for the quarter, compared to the consensus estimate of $4.50 billion. During the same quarter in the previous year, the firm posted $0.90 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis.

Several analysts recently issued reports on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 price objective on shares of Danaher Corporation in a report on Friday. BidaskClub downgraded shares of Danaher Corporation from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Wells Fargo & Company assumed coverage on shares of Danaher Corporation in a report on Thursday, July 13th. They set a “market perform” rating and a $90.00 price objective for the company. Zacks Investment Research downgraded shares of Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. Finally, BTIG Research reaffirmed a “buy” rating and set a $92.00 price objective on shares of Danaher Corporation in a report on Sunday, April 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $91.76.

Shares of Danaher Corporation (NYSE DHR) opened at 81.01 on Monday. Danaher Corporation has a 1-year low of $75.71 and a 1-year high of $88.01. The stock has a market cap of $56.28 billion, a P/E ratio of 25.86 and a beta of 1.03. The company’s 50-day moving average is $83.93 and its 200 day moving average is $84.29.

The business also recently announced a quarterly dividend, which was paid on Friday, July 28th. Investors of record on Friday, June 30th were paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Wednesday, June 28th. Danaher Corporation’s payout ratio is currently 17.83%.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/zacks-analysts-anticipate-danaher-corporation-dhr-to-post-0-95-eps.html.

In related news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the transaction, the insider now directly owns 155,520 shares in the company, valued at approximately $12,718,425.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Angela S. Lalor sold 10,815 shares of the company’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $84.16, for a total transaction of $910,190.40. Following the transaction, the senior vice president now owns 39,020 shares of the company’s stock, valued at $3,283,923.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,623 shares of company stock valued at $3,206,426. Corporate insiders own 12.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Mosaic Family Wealth LLC boosted its position in shares of Danaher Corporation by 120.7% in the second quarter. Mosaic Family Wealth LLC now owns 3,788 shares of the conglomerate’s stock worth $320,000 after buying an additional 2,072 shares in the last quarter. Cadence Capital Management LLC boosted its position in shares of Danaher Corporation by 1.4% in the second quarter. Cadence Capital Management LLC now owns 17,821 shares of the conglomerate’s stock worth $1,504,000 after buying an additional 241 shares in the last quarter. Montag A & Associates Inc. acquired a new position in shares of Danaher Corporation during the second quarter worth about $542,000. Progressive Investment Management Corp boosted its position in shares of Danaher Corporation by 314.0% in the second quarter. Progressive Investment Management Corp now owns 33,317 shares of the conglomerate’s stock worth $2,812,000 after buying an additional 25,269 shares in the last quarter. Finally, iAB Financial Bank acquired a new position in shares of Danaher Corporation during the second quarter worth about $228,000. Institutional investors own 76.56% of the company’s stock.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher Corporation (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.